We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.
hematopoietic toxicity
MTX
immunosuppression
MTX
EBV-associated lymphoproliferative disease
MTX